Wave Life Sciences reported a quarterly loss of $0.34 per share, slightly worse than the Zacks Consensus Estimate of $0.31. Revenues also fell short, totaling $2.27 million, down 73.48% year-over-year. The company has missed earnings expectations in three of the last four quarters, and its stock has declined about 65.8% in 2023, significantly underperforming the S&P 500’s 6.9% gain. Despite recent struggles, the earnings outlook shows some improvement, earning a Zacks Rank of #2 (Buy), indicating potential for near-term stock outperformance. Future performance will depend heavily on management’s commentary and adjustments in earnings estimates.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/wave-life-sciences-wve-reports-133508268.html
